Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Anavex Life Sciences (AVXL) Stock Price & Analysis

1,760 Followers

AVXL Stock Chart & Stats

$1.11-$0.15(-11.90%)
At close: 4:00 PM EST
$1$2$3Aug 10Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2
Day’s Range
$1.07 - $1.26
52-Week Range
$1.07 - $7.60
Previous Close
$1.26
Volume
N/A
Average Volume (3M)
1.36M
Market Cap
$116.80M
Enterprise Value
$122.28M
Total Cash (Recent Filing)
$118.33M
Total Debt (Recent Filing)
$0
Price to Earnings (P/E)
―
Beta
2.19
Next Earnings
Nov 30, 2026 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Debt-free Balance Sheet

The absence of debt lowers refinancing and interest-burden risk while preserving flexibility to fund clinical development. Although capital is being consumed by losses, a debt-free structure gives Anavex more room to manage financing and allocate resources as programs advance.

Broadening CNS Pipeline

Progress across Alzheimer’s disease, Rett syndrome and Fragile X syndrome gives Anavex multiple clinical pathways around its lead asset. A broader indication portfolio can diversify development outcomes and expand future commercial potential if clinical and regulatory milestones are achieved.

Experienced Permanent Leadership

Installing an experienced permanent CEO strengthens accountability during an important development stage. Kellmeyer’s background in clinical development, regulatory affairs, operations and medical affairs is directly relevant to advancing trials, preparing filings and maintaining regulatory execution.

Bears Say

No Commercial Revenue

Without product revenue, Anavex remains dependent on successful clinical development and eventual regulatory commercialization to establish an operating business. Continued losses leave earnings visibility weak and make future financial performance highly contingent on pipeline outcomes.

Persistent Cash Burn

Ongoing negative operating and free cash flow means the company is not internally funding its development plans. Even with modest recent improvement, continued cash burn increases reliance on external funding and can constrain the pace or scale of future clinical investment.

Governance Instability

Multiple director resignations tied to disagreements with management and strategy create governance uncertainty while Anavex is executing clinical and regulatory plans. Committee changes and the search for another independent director may distract oversight and complicate consistent strategic decision-making.

Anavex Life Sciences News

AVXL FAQ

What was Anavex Life Sciences’s price range in the past 12 months?
Anavex Life Sciences lowest stock price was $1.07 and its highest was $7.60 in the past 12 months.
What is Anavex Life Sciences’s market cap?
Anavex Life Sciences’s market cap is $116.80M.
When is Anavex Life Sciences’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Anavex Life Sciences’s earnings last quarter?
Anavex Life Sciences released its earnings results on Jul 30, 2026. The company reported $0.08 earnings per share for the quarter.
Is Anavex Life Sciences overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Anavex Life Sciences pay dividends?
Anavex Life Sciences does not currently pay dividends.
What is Anavex Life Sciences’s EPS estimate?
Anavex Life Sciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Anavex Life Sciences have?
Anavex Life Sciences has 92,696,840 shares outstanding.
What happened to Anavex Life Sciences’s price movement after its last earnings report?
Anavex Life Sciences reported an EPS of $0.08 in its last earnings report. Following the earnings report the stock price went up 8.434%.
Which hedge fund is a major shareholder of Anavex Life Sciences?
Hedge funds hold Anavex Life Sciences shares: the largest hedge-fund position in Anavex Life Sciences is 71,883,978 shares, and hedge funds increased their holdings by 446.0K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology